| Hari Dandapantula, MD | |
|
2401 S 31st St, Temple, TX 76508-2381 | |
| (254) 724-2111 | |
| (254) 724-7603 |
| Full Name | Hari Dandapantula |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 23 Years |
| Location | 2401 S 31st St, Temple, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487604112 | NPI | - | NPPES |
| HD072495 | Other | MI | BCBSM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | M9947 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Pavilion - Temple | Temple, TX | Hospital |
| Baylor Scott & White Medical Center - Round Rock | Round rock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scott And White Clinic | 8123923604 | 2131 |
News Archive
A key brain protein called monoamine oxidase A (MAO-A) - is highly elevated during clinical depression yet is unaffected by treatment with commonly used antidepressants, according to an important study published today in the Archives of General Psychiatry. The study has important implications for our understanding of why antidepressants don't always work.
Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).
OPKO Health, Inc. today announced that it has entered into a definitive agreement with Schering-Plough Corporation to acquire assets relating to Schering's neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.
Cutting-edge European research presented at the 2014 AAAS meeting in Chicago. Three leading European researchers on the gut microbiome will be present at the 2014 AAAS meeting, on Saturday 15 February, to share their recent findings on the relations between gut flora and obesity, diabetes, and cardio-metabolic diseases in general.
Working with a multidisciplinary consortium of 19 researchers from nine institutions, Monell scientists have provided critical information to identify CALHM1, a channel in the walls of taste receptor cells, as a necessary component in the process of sweet, bitter, and umami (savory) taste perception.
› Verified 5 days ago
| Entity Name | Scott & White Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093779704 PECOS PAC ID: 8123923604 Enrollment ID: O20031223000640 |
News Archive
A key brain protein called monoamine oxidase A (MAO-A) - is highly elevated during clinical depression yet is unaffected by treatment with commonly used antidepressants, according to an important study published today in the Archives of General Psychiatry. The study has important implications for our understanding of why antidepressants don't always work.
Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).
OPKO Health, Inc. today announced that it has entered into a definitive agreement with Schering-Plough Corporation to acquire assets relating to Schering's neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.
Cutting-edge European research presented at the 2014 AAAS meeting in Chicago. Three leading European researchers on the gut microbiome will be present at the 2014 AAAS meeting, on Saturday 15 February, to share their recent findings on the relations between gut flora and obesity, diabetes, and cardio-metabolic diseases in general.
Working with a multidisciplinary consortium of 19 researchers from nine institutions, Monell scientists have provided critical information to identify CALHM1, a channel in the walls of taste receptor cells, as a necessary component in the process of sweet, bitter, and umami (savory) taste perception.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hari Dandapantula, MD Po Box 844658, Dallas, TX 75284-4658 Ph: (254) 724-8800 | Hari Dandapantula, MD 2401 S 31st St, Temple, TX 76508-2381 Ph: (254) 724-2111 |
News Archive
A key brain protein called monoamine oxidase A (MAO-A) - is highly elevated during clinical depression yet is unaffected by treatment with commonly used antidepressants, according to an important study published today in the Archives of General Psychiatry. The study has important implications for our understanding of why antidepressants don't always work.
Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).
OPKO Health, Inc. today announced that it has entered into a definitive agreement with Schering-Plough Corporation to acquire assets relating to Schering's neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.
Cutting-edge European research presented at the 2014 AAAS meeting in Chicago. Three leading European researchers on the gut microbiome will be present at the 2014 AAAS meeting, on Saturday 15 February, to share their recent findings on the relations between gut flora and obesity, diabetes, and cardio-metabolic diseases in general.
Working with a multidisciplinary consortium of 19 researchers from nine institutions, Monell scientists have provided critical information to identify CALHM1, a channel in the walls of taste receptor cells, as a necessary component in the process of sweet, bitter, and umami (savory) taste perception.
› Verified 5 days ago
Raagsudha Jhavar, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1605 S 31st St, Temple, TX 76508 Phone: 254-215-0100 Fax: 254-215-0636 | |
Dr. John L. Carpenter, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Dr. Farrukh Sarmad Badsha, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St # Msa1300, Temple, TX 76508 Phone: 254-935-5820 | |
Dr. Seetha Kannan, M.D Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2409 Pin Oak Dr, Temple, TX 76502 Phone: 254-774-8060 | |
Jennifer D Moran, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Dr. Douglas Randall Bretzing, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2364 | |
Dr. Patrick Ramirez, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2364 Fax: 254-724-7603 |